{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:42Z","timestamp":1787759322676,"version":"build-2784847793"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Carbapenem-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae<\/jats:named-content>\n            (CRKP) is an increasingly common cause of health care-associated urinary tract infections. Antimicrobials with\n            <jats:italic>in vitro<\/jats:italic>\n            activity against CRKP are typically limited to polymyxins, tigecycline, and often, aminoglycosides. We conducted a retrospective cohort study of cases of CRKP bacteriuria at New York-Presbyterian Hospital from January 2005 through June 2010 to compare microbiologic clearance rates based on the use of polymyxin B, tigecycline, or an aminoglycoside. We constructed three active antimicrobial cohorts based on the active agent used and an untreated cohort of cases that did not receive antimicrobial therapy with Gram-negative activity. Microbiologic clearance was defined as having a follow-up urine culture that did not yield CRKP. Cases without an appropriate follow-up culture or that received multiple active agents or less than 3 days of the active agent were excluded. Eighty-seven cases were included in the active antimicrobial cohorts, and 69 were included in the untreated cohort. The microbiologic clearance rate was 88% in the aminoglycoside cohort (\n            <jats:italic>n<\/jats:italic>\n            = 41), compared to 64% in the polymyxin B (\n            <jats:italic>P<\/jats:italic>\n            = 0.02;\n            <jats:italic>n<\/jats:italic>\n            = 25), 43% in the tigecycline (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001;\n            <jats:italic>n<\/jats:italic>\n            = 21), and 36% in the untreated (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001;\n            <jats:italic>n<\/jats:italic>\n            = 69) cohorts. Using multivariate analysis, the odds of clearance were lower for the polymyxin B (odds ratio [OR], 0.10;\n            <jats:italic>P<\/jats:italic>\n            = 0.003), tigecycline (OR, 0.08;\n            <jats:italic>P<\/jats:italic>\n            = 0.001), and untreated (OR, 0.14;\n            <jats:italic>P<\/jats:italic>\n            = 0.003) cohorts than for the aminoglycoside cohort. Treatment with an aminoglycoside, when active\n            <jats:italic>in vitro<\/jats:italic>\n            , was associated with a significantly higher rate of microbiologic clearance of CRKP bacteriuria than treatment with either polymyxin B or tigecycline.\n          <\/jats:p>","DOI":"10.1128\/aac.00387-11","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T04:10:31Z","timestamp":1317701431000},"page":"5893-5899","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":111,"title":["Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine"],"prefix":"10.1128","volume":"55","author":[{"given":"Michael J.","family":"Satlin","sequence":"first","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Kubin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S.","family":"Blumenthal","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Yoko","family":"Furuya","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Calfee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00015-07"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/526775"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.12.1430"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.3018-3020.2005"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki175"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01114-07"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2007.19.6.753"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02494-07"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq224"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01367-09"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/591861"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00126-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01340-07"},{"key":"e_1_3_2_16_2","first-page":"538","article-title":"Influence of dose in the urinary excretion of amikacin","volume":"22","author":"Lanao J. M.","year":"1984","unstructured":"LanaoJ. M. PedrazJ. L. NavarroA. S. Dominguez-GilA.. 1984. Influence of dose in the urinary excretion of amikacin. Int. J. Clin. Pharmacol. Ther. Toxicol. 22:538\u2013542.","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh167"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M277"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70054-4"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K346"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.8.1198"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.Supplement-1.12"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.12.019"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2591"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm193"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1973145815"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/592577"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00387-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00387-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:22:08Z","timestamp":1645485728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00387-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1128\/AAC.00387-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00387-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"2011-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}